Histologically confirmed peripheral T-cell lymphoma (PTCL), including PTCL-NOS, AITL, ALCL, or NKTCL
Received at least one prior systemic therapy and prior exposure to at least one novel agent (e.g., chidamide, pralatrexate, brentuximab vedotin, etc.) or refractory/intolerant to such therapies
Age ≥18 years
ECOG performance status 0-1
At least one measurable lesion per Lugano 2014 criteria (lymph node ≥1.5 cm in longest diameter or extranodal lesion ≥1.0 cm)
Adequate organ function, defined as: ANC ≥1.5 × 10⁹/L, Platelets ≥100 × 10⁹/L, Hemoglobin ≥100 g/L, Total bilirubin ≤1.5 × ULN, ALT/AST ≤2.5 × ULN (≤5 × ULN if liver involvement), Creatinine clearance ≥50 mL/min (Cockcroft-Gault), LVEF ≥50%, QTcF \<450 ms (male), \<470 ms (female)
Willingness to provide archival or fresh tumor tissue
Life expectancy ≥3 months
You may not be if
Prior treatment with EZH2 or EZH1/2 inhibitors resulting in disease progression (intolerance permitted)
Known central nervous system involvement of lymphoma
Active uncontrolled infection requiring systemic therapy
Significant or uncontrolled cardiovascular disease
Prior allogeneic stem cell transplantation or autologous stem cell transplantation within 90 days prior to first dose
Pregnancy or lactation, or unwillingness to use effective contraception
Other malignancies within 5 years, except adequately treated basal cell carcinoma, squamous cell carcinoma, carcinoma in situ, or thyroid carcinoma
Patients planned to receive mitoxantrone liposomal therapy with prior cumulative doxorubicin exposure ≥350 mg/m² (or equivalent anthracycline exposure)
